Pharmaceuticals
Fosun International Issues Positive Profit Alert: Profit Attributable to Owners of the Parent for 1H2026 Expected to be Approx. RMB 1.5 Billion to RMB1.8 Billion
HONG KONG, July 29, 2026 /PRNewswire/ -- On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of app...
2026-07-29 17:35
4276
AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer
* ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have received one to three prior s...
2026-07-29 10:00
2730
IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...
2026-07-28 18:44
1749
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Fi...
2026-07-27 23:17
3335
Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
* STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive cases * Findings support the potential value of a comprehensive testing approach that provides both HPV and STI pathogen information * Seegene to v...
2026-07-27 21:00
7192
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
TAIPEI, July 27, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics,today reaffirmed its strategic focus on pursuing global li...
2026-07-27 20:20
3507
Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
* Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. * Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volum...
2026-07-27 20:10
3918
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)...
2026-07-27 19:40
4072
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA...
2026-07-27 18:42
4572
Jiangxi Bio's Veterinary Tetanus Antitoxin Production Line Officially Commenced Production,Accelerating Commercialization of the Animal Antiserum Portfolio
HONG KONG, July 27, 2026 /PRNewswire/ -- Jiangxi Institute of Biological Products Inc. and its subsidiaries (collectively, "Jiangxi Bio" or the "Group") (stock code: 6915.HK) is pleased to announce that the veterinary tetanus antitoxin ("Veterinary TAT") production line of Chifeng Bo-en Pharmaceu...
2026-07-27 15:36
6033
IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...
2026-07-27 11:00
1911
Seaweed extract shown to relieve prostate symptoms
In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical...
2026-07-27 07:00
1617
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...
2026-07-24 09:30
2185
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...
2026-07-24 09:00
2773
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...
2026-07-23 08:10
3833
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...
2026-07-22 20:28
4267
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Funding will support completion of IND-enabling activities and planned year-end
IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate
targeting B7-H3-positive solid tumors
SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd.
2026-07-22 19:03
3608
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026
As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health. SINGAPORE, July 22, 2026 /PRNewswire/ -- Gene ...
2026-07-22 11:59
3625
Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations
* The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1] * Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against deng...
2026-07-21 16:41
3569
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] * Group revenue of US...
2026-07-21 06:52
5730
Week's Top Stories
Most Reposted
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13957
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12660
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11746
